A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2019; you can also visit the original URL.
The file type is application/pdf.
Cost-effectiveness of zoledronic acid and strontium-89 as bone protecting treatments in addition to chemotherapy in patients with metastatic castrate-refractory prostate cancer: results from the TRAPEZE trial (ISRCTN 12808747)
2016
BJU International
Preserved Fulltext
Conclusions The addition of bone-targeting treatments to standard chemotherapy led to a small improvement in QALYs for a modest increase in cost (or cost-savings). ZA and Sr89 resulted in ICERs below conventional willingness-to-pay per QALY thresholds, suggesting that their addition to chemotherapy may represent a cost-effective use of resources. Keywords castrate-refractory prostate cancer, cost-effectiveness analysis, quality of life, bone protecting treatments, zoledronic acid, Sr89
doi:10.1111/bju.13549
pmid:27256016
fatcat:p6nncl2fuvh5fntoxcft5ambny